Tissue Core-UNMC Rapid Autopsy Program

项目概要 摘要 该 ARTNet 应用程序中的所有项目都将使用未识别身份的人类标本进行针对以下目标的研究： 了解胰腺导管腺癌的获得性耐药性。为了提供 为了获得必要的标本，组织核心已与 内布拉斯加大学医学中心 (UNMC) 组织库，旨在提供协调一致的组织库 集中核心致力于采购、处理和分发生物样本及相关的设计 确定的临床数据。快速尸检计划 (RAP) 核心设施存储正常、良性（即急性 和/或慢性纤维化胰腺炎）和恶性胰腺组织（包括原发性和转移性胰腺组织） 胰腺癌以及神经内分泌肿瘤）和外周血淋巴细胞、血浆和 来自接受胰腺恶性肿瘤手术的患者和死者的血清 有胰腺癌病史的患者（快速尸检）。非癌症供体全胰腺、脾脏、 还与当地合作收集十二指肠、肝脏、肺、肌肉、淋巴结和肾上腺组织 器官获取机构。 RAP 生物样本库还与外科和肿瘤学以及 几个完善的 UNMC 患者监测计划，例如 PCCDC 和 PCCR，以制定 前期、早期和末期组织和生物流体样本集的稳健纵向收集。重要的是， 目前快速尸检项目提供的存档样本是基于 UNMC 的资源 代表研究 PDAC 疾病获得性耐药性所需的确切样本集，以及 资源的持续增长只会增强UNMC研究抗病能力的能力。的 core 还维护了所有癌症研究人员可用的各种资源的缓存，例如疾病和 正常 TMA、供体样本序列分析和新鲜组织采集。该银行包括一个 数据库管理和样本分发机制（Freezerworks）和统一的系统 组织库监督委员会已确定和使用所请求材料的优先顺序。 该核心设施旨在有利于 ARTNet 的具体研究活动以及研究 UNMC 内外专注于转化研究的其他科学家的活动 问题和阻力机制。 只有在所有其他诊断程序之后从有临床指征的手术中获得的样本才具有 完成的结果将提交给 UNMC ARTNet 组织库进行耐药性研究。的 否则标本将被丢弃或处置。符合条件的患者有机会参与 提交书面知情同意书。患者不会面临任何风险，也不会影响患者的护理， 因为无论收集需要如何，执行的所有程序都将用于诊断。 。

Project Summary Abstract All projects in this ARTNet application will use deidentified human specimens for research directed at understanding acquired resistance to therapy in pancreatic ductal adenocarcinoma. In order to provide the necessary specimens, a Tissue Core has been developed in cooperation with and under the auspices of the University of Nebraska Medical Center (UNMC) Tissue Bank, with the goal of providing a coordinated and centralized core dedicated to procuring, processing and distributing biological specimens and associated de- identified clinical data. The Rapid Autopsy Program (RAP) core facility stores normal, benign (i.e. acute and/or chronic fibrosing pancreatitis) and malignant pancreatic tissues (including both primary and metastatic pancreatic carcinomas as well as neuroendocrine tumors) and peripheral blood lymphocytes, plasma and serum from patients undergoing surgical procedures for pancreatic malignancies and from deceased patients with a history of pancreatic cancer (rapid autopsy). Non-cancer donor whole pancreata, spleen, duodenum, liver, lung, muscle, lymph node and adrenal tissue are also collected in collaboration with local organ procurement agencies. The RAP biorepository also coordinates with surgery and oncology, as well as several well-established UNMC patient monitoring programs, such as the PCDC and PCCR, to develop robust longitudinal collections of pre, early, and end-stage tissue and biofluid sample sets. Importantly, the currently archived samples available from the rapid autopsy program are a UNMC-based resource representing the exact sample sets necessary to investigate acquired resistance in PDAC disease and continued growth of the resource will only serve to enhance UNMC’s ability to study disease resistance. The core also maintains a cache of various resources available to all cancer investigators, such as disease and normal TMAs, donor sample sequence analysis and fresh tissue acquisition. The bank includes a mechanism for database management and specimen distribution (Freezerworks) and a uniform system of prioritization of requested materials has been defined and used by the Tissue Bank Oversight Committee. This core facility is intended to benefit the specific research activities of the ARTNet, as well as the research activities of other scientists within and outside of UNMC who are concentrating on translational research issues and resistance mechanisms. Only specimens obtained from clinically indicated surgeries after all other diagnostic procedures have been performed will be submitted to the UNMC ARTNet tissue bank for resistance research. The specimens would otherwise be discarded or disposed. Eligible patients have the opportunity to participate by submitting written informed consent. There is no risk to the patient or compromise to the patient's care, as all the procedures performed would be performed for diagnostics regardless of the collection need. .